305 results
6-K
EX-1
BLRX
Bioline Rx Ltd
13 Oct 11
Current report (foreign)
12:00am
on such Office Holder in favor of any other person;
reasonable litigation expenses, including attorneys fees, incurred by the Office Holder as a result … litigation expenses including attorney's fees, incurred by him as a result of an investigation or proceedings instituted against him by an authority
20FR12B
EX-4.29
BLRX
Bioline Rx Ltd
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
and all costs of such litigation, including attorneys’ fees. The Company shall not compromise or settle such litigation, or acquire a license to any … third party intellectual property in order to settle or bring to a conclusion such litigation, without the prior written consent of Yissum, which
6-K
EX-99.3
BLRX
Bioline Rx Ltd
3 Mar 14
Current report (foreign)
12:00am
patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs … of such litigation or proceedings more effectively because of their substantially greater financial resources. Uncertainties resulting from the initiation
F-1
EX-10.16
BLRX
Bioline Rx Ltd
24 Sep 10
Registration statement (foreign)
12:00am
for entirely by BioLine and BioLine shall hold Licensor free, clear and harmless from and against any and all costs of such litigation, including reasonable … attorneys’ fees. BioLine shall not compromise or settle such litigation without the prior written consent of Licensor, which consent shall
20FR12B
EX-4.6
khru t9kkay8vk6
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
20FR12B
EX-4.16
jweyqi qo28b2oeu1g
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
F-1
EX-10.6
xqr7g g85k4
24 Sep 10
Registration statement (foreign)
12:00am
6-K
EX-99.1
vzpgyjp
7 Mar 14
BioLineRx Closes $24.1 Million Underwritten Public Offering
12:00am
6-K
EX-99.1
24gtr7m t4keto
13 Feb 13
BioLineRx Announces Closing of $8 Million Offering of American
12:00am
6-K
EX-99
p7q2hxg7520wm54xe
28 Jun 19
BioLineRx Announces Change in Ratio of American
4:01pm
6-K
EX-99.3
88w6uladqlu15a976
5 Mar 15
Current report (foreign)
12:00am
F-3/A
g156rrhpy
13 Aug 12
Shelf registration (foreign) (amended)
12:00am
6-K
EX-99.2
1tol2nis689
3 Mar 14
Current report (foreign)
12:00am
6-K
EX-99.1
upeanuo
22 Jan 21
BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of
4:21pm
6-K
EX-99
f0v8mal
7 Mar 12
BioLineRx Announces Grant of European Patent Covering
12:00am
6-K
EX-99.1
9nyap5og
7 Feb 19
As Representative of the several Underwriters
12:00pm
6-K
EX-99.1
ug6k pzgx
16 Feb 12
Current Report, Foreign Issuer
12:00am
6-K
EX-99.2
r6lg5jzqggfwun3id6
4 Feb 19
Current report (foreign)
4:30pm
6-K
EX-99.1
lnk2iry
27 Feb 12
BioLineRx Ltd. Announces Closing of $15 millionPrivate Placement to Institutional Investors
12:00am